Literature DB >> 24935789

Role(s) of the 5-HT2C receptor in the development of maximal dentate activation in the hippocampus of anesthetized rats.

Gergely Orban1, Cristiano Bombardi, Antonella Marino Gammazza, Roberto Colangeli, Massimo Pierucci, Cristoforo Pomara, Mauro Pessia, Fabio Bucchieri, Arcangelo Benigno, Benigno Arcangelo, Ilse Smolders, Philippe De Deurwaerdère, Giuseppe Di Giovanni.   

Abstract

AIMS: Substantial evidence indicates that 5-HT2C receptors are involved in the control of neuronal network excitability and in seizure pathophysiology. Here, we have addressed the relatively unexplored relationship between temporal lobe epilepsy (TLE), the most frequent type of intractable epilepsy, and 5-HT2CRs.
METHODS: In this study, we investigated this issue using a model of partial complex (limbic) seizures in urethane-anesthetized rat, based on the phenomenon of maximal dentate activation (MDA) using 5-HT2C compounds, electrophysiology, immunohistochemistry, and western blotting techniques.
RESULTS: The 5-HT2C agonists mCPP (1 mg/kg, i.p) and lorcaserin (3 mg/kg, i.p), but not RO60-0175 (1-3 mg/kg i.p.), were antiepileptogenic reducing the MDA response duration. The selective 5-HT2C antagonist SB242084 (2 mg/kg, i.p) unveiled antiepileptogenic effects of RO60-0175 (3 mg/kg, i.p) but did not alter those induced by mCPP and lorcaserin. Compared with control rats, electrically stimulated rats showed an increase in glutamic acid decarboxylase levels and a heterogeneous decrease in 5-HT2CR immunoreactivity in different hippocampal areas.
CONCLUSIONS: In our animal model of TLE, mCPP and lorcaserin were anticonvulsant; likely acting on receptor subtypes other than 5-HT2C. Epileptogenesis induced early adaptive changes and reorganization in the 5-HT2CR and GABA systems.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Dentate gyrus; Depression; GABA; Memory; Serotonergic2c drugs; Serotonin receptors; Temporal lobe epilepsy

Mesh:

Substances:

Year:  2014        PMID: 24935789      PMCID: PMC6493041          DOI: 10.1111/cns.12285

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  15 in total

Review 1.  Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Authors:  Julie Ziobro; Krista Eschbach; Joseph E Sullivan; Kelly G Knupp
Journal:  Curr Treat Options Neurol       Date:  2018-10-13       Impact factor: 3.598

2.  Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.

Authors:  Melissa L Barker-Haliski; Kristina Johnson; Peggy Billingsley; Jennifer Huff; Laura J Handy; Rizvana Khaleel; Zhenmei Lu; Matthew J Mau; Timothy H Pruess; Carlos Rueda; Gerald Saunders; Tristan K Underwood; Fabiola Vanegas; Misty D Smith; Peter J West; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-03-16       Impact factor: 3.996

Review 3.  Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?

Authors:  Meir Bialer; Emilio Perucca
Journal:  CNS Drugs       Date:  2022-01-30       Impact factor: 5.749

4.  Preferential modulation of the lateral habenula activity by serotonin-2A rather than -2C receptors: Electrophysiological and neuroanatomical evidence.

Authors:  Francis Delicata; Cristiano Bombardi; Massimo Pierucci; Roberto Di Maio; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  CNS Neurosci Ther       Date:  2018-02-25       Impact factor: 5.243

5.  Lateral Habenula 5-HT2C Receptor Function Is Altered by Acute and Chronic Nicotine Exposures.

Authors:  Cristiano Bombardi; Francis Delicata; Claudio Tagliavia; Annamaria Grandis; Massimo Pierucci; Antonella Marino Gammazza; Maurizio Casarrubea; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

6.  Inhibition of hyperactivity of the dorsal raphe 5-HTergic neurons ameliorates hippocampal seizure.

Authors:  Heming Cheng; Yingbei Qi; Nanxi Lai; Lin Yang; Cenglin Xu; Shuang Wang; Yi Guo; Zhong Chen; Yi Wang
Journal:  CNS Neurosci Ther       Date:  2021-05-06       Impact factor: 5.243

7.  Hsp60 response in experimental and human temporal lobe epilepsy.

Authors:  Antonella Marino Gammazza; Roberto Colangeli; Gergely Orban; Massimo Pierucci; Giancarlo Di Gennaro; Margherita Lo Bello; Alfredo D'Aniello; Fabio Bucchieri; Cristoforo Pomara; Mario Valentino; Richard Muscat; Arcangelo Benigno; Giovanni Zummo; Everly Conway de Macario; Francesco Cappello; Giuseppe Di Giovanni; Alberto J L Macario
Journal:  Sci Rep       Date:  2015-03-24       Impact factor: 4.379

Review 8.  Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?

Authors:  Bruno P Guiard; Giuseppe Di Giovanni
Journal:  Front Pharmacol       Date:  2015-03-17       Impact factor: 5.810

9.  Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures.

Authors:  Marcello Venzi; François David; Joachim Bellet; Anna Cavaccini; Cristiano Bombardi; Vincenzo Crunelli; Giuseppe Di Giovanni
Journal:  Neuropharmacology       Date:  2016-04-13       Impact factor: 5.250

10.  Evaluation of lorcaserin as an anticonvulsant in juvenile Fmr1 knockout mice.

Authors:  Tanishka S Saraf; Daniel E Felsing; Jessica L Armstrong; Raymond G Booth; Clinton E Canal
Journal:  Epilepsy Res       Date:  2021-05-27       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.